Phase 2 Heart Disease Trial, Recruiting NCT06501768 Sponsor: University Medical Centre Ljubljana Condition: Heart Disease
Back to Heart Disease

Phase 2 Heart Disease Trial, Recruiting

NCT06501768
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have heart failure (caused either by blocked arteries or by other heart conditions) where the heart's pumping strength is below 40%
  • People who have a heart condition called ATTR cardiomyopathy (a disease where abnormal proteins build up in the heart), regardless of how well the heart is pumping
  • People whose heart failure treatments have been stable and at the best tolerated doses for at least 3 months, with no changes to medications for at least 1 month
  • People whose blood test shows a protein called NT-proBNP is above 350 pg/mL (a marker that indicates heart stress)

Who may not be able to join:

  • People who have had a heart procedure (such as a stent or bypass) within the past 3 months
  • People who are pregnant
  • People who have cancer
  • People who follow a vegan diet
  • People who take certain supplements, including isoflavonoids or resveratrol
  • People who drink alcohol above certain limits (for men: more than 4 drinks on any single day or more than 14 drinks per week; for women: more than 3 drinks on any single day or more than 7 drinks per week)
  • People with significant liver problems, based on specific blood test results (confirm with trial site)
  • People with significant kidney problems, based on a kidney function score below 25 mL/min/1.73m² (confirm with trial site)
  • People with poorly controlled diabetes, based on a blood sugar control test result above 10% (confirm with trial site)
  • People with blood clotting disorders
  • People with certain low blood count results, including low white blood cells, low red blood cells (haemoglobin below 9 mg/dL), or low platelets (confirm with trial site)
  • People who have been hospitalised in the past 3 months for any reason other than heart failure
  • People whose heart failure symptoms fall into the mildest category (no symptoms) or the most severe category (symptoms at rest), based on a standard heart failure classification system
  • People who currently have an active bacterial or viral infection, or a flare-up of a long-term infection
  • People with a known allergy or sensitivity to soy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +3861 522 1157

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University Medical Centre Ljubljana
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇸🇮 Slovenia

Primary endpoints

HF inflammatory and cardiometabolic markers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov